Trial Profile
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Torasemide
- Indications Tricuspid valve insufficiency
- Focus Therapeutic Use
- 25 Sep 2018 Primary endpoint (The change of all the subjectsliquid intake and output volume change after a period(10 days) of treatment) has been met, according to results published in the American Journal of Cardiovascular Drugs.
- 25 Sep 2018 Results published in the American Journal of Cardiovascular Drugs
- 19 Dec 2016 Status changed from recruiting to completed.